Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis

A technology of pyrroloquinoline quinone and liver fibrosis, applied in the treatment and/or prevention of liver fibrosis, in the field of pyrroloquinoline quinone, can solve the preventive and/or therapeutic effects of PQQ active substances And other issues

Inactive Publication Date: 2013-08-14
SHANGHAIMED
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0012] However, before the present invention, this area has never done research on the preventive and / or therapeutic effects of PQQ active substances on liver fibrosis and its related symptoms and / or diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis
  • Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis
  • Application of pyrroloquinoline quinone in treatment and/or prevention of liver fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0100] Example 1. PQQ pretreatment inhibits TAA-induced upregulation of α-SMA and collagen expression in mouse liver tissue

[0101] In order to detect whether PQQ has a protective effect on liver fibrosis caused by thioacetamide (TAA), the inventor first constructed a TAA mouse model of liver fibrosis, and treated it with different doses of PQQ by intragastric administration, and observed the effect of PQQ on the liver fibrosis caused by TAA. The pathological morphology of fibrosis and the expression and distribution of α-smooth muscle actin (α-SMA).

[0102] Modeling and dosage:

[0103]

[0104] Animal grouping and dosing:

[0105] Healthy BALB / c mice, male, 4-6 weeks old, were purchased from Shanghai Experimental Animal Center, Chinese Academy of Sciences. The mice were randomly divided into 4 groups, normal group (marked as "N" in the figure, 10), model group (marked as "M" in the figure, 10), PQQ low-dose group (marked as "L" in the figure) ", 10 rats), PQQ hig...

Embodiment 2

[0160] Example 2. PQQ pretreatment reduces transaminase levels in serum of mice treated with TAA

[0161] Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are important indicators of liver damage. In this example, the effect of PQQ treatment on mouse serum ALT and AST was further verified.

[0162] Material:

[0163] The following kits were purchased from Nanjing Jiancheng Institute of Bioengineering:

[0164] Aspartate Aminotransferase (AST / GOT) Assay Kit (Rei's method)

[0165] Alanine aminotransferase (ALT / GPT) assay kit (Rei's method)

[0166] experimental method:

[0167] As in Example 1, it is a batch of animals, and the administration method in groups is the same as that in Example 1.

[0168] Eyeballs were picked from the mice to collect blood, which was collected in Eppendorf tubes, left at room temperature for 4 hours, centrifuged at 3000rpm for 10min, serum was separated, and stored at -80°C for later use.

[0169] The detection methods o...

Embodiment 3

[0172] Example 3. PQQ pretreatment improves antioxidant capacity in TAA-treated mouse liver

[0173]Since oxidative stress plays an important role in the occurrence of liver fibrosis, the inventors further tested the effect of PQQ treatment on redox-related indicators in the liver of mice.

[0174] Material:

[0175] The following kits were purchased from Nanjing Jiancheng Institute of Bioengineering:

[0176] Catalase (CAT) assay kit (visible light method);

[0177] Malondialdehyde (MDA) assay kit;

[0178] Superoxide dismutase (SOD) assay kit.

[0179] experimental method:

[0180] As in Example 1, it is a batch of animals, and the administration method in groups is the same as that in Example 1.

[0181] Homogenate: take 0.5 g of tissue block (the mouse liver tissue obtained in Example 1 is divided into Eppendorf tubes and then quickly frozen in liquid nitrogen, and stored at -80°C for later use), and 1 ml of 0.86% cold normal saline is used as homogenate Medium, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of pyrroloquinoline quinone in treatment and / or prevention of liver fibrosis. The present invention provides application of a pyrroloquinoline quinone active substance in the preparation of a composition for treatment and / or prevention of object liver fibrosis or related symptoms or related diseases, and also provides pyrroloquinoline quinine-containing health care compositions or pharmaceutical compositions. The pyrroloquinoline quinone of the invention can improve the antioxidant capacity of liver tissues, inhibit expression of alpha-smooth muscle actin and type I collagen, relieve inflammation of liver, and can antagonize the induced differentiation and promoting activation of a transforming growth factor-beta for hepatic stellate cells. Therefore, the pyrroloquinoline quinone has a good application prospect in prevention and / or treatment of liver fibrosis formation and development.

Description

technical field [0001] The present invention relates to the field of disease prevention and / or treatment. More specifically, the present invention relates to the application of pyrroloquinoline quinone in the treatment and / or prevention of liver fibrosis. Background technique [0002] Liver cirrhosis is a common disease in my country and one of the main diseases that endanger human health and life. The onset is insidious, the complications are serious, and the prognosis is poor. There is no effective treatment method in clinical practice. [0003] Hepatic fibrosis is the pre-pathological change of liver cirrhosis. There are many etiologies, among which viral hepatitis, alcoholic hepatitis, fatty liver and autoimmune diseases are common clinically. [0004] The vast majority of chronic liver diseases have liver fibrosis, and 25% to 40% of them eventually develop into liver cirrhosis or even liver cancer. Liver fibrosis is a histological change in the late stage of chronic ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4745A61P1/16
Inventor 张颂文阮元元贾冬威顾建新恽小婧孙琳琳周蕾
Owner SHANGHAIMED
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com